Skip to content

Rheumatoid arthritis — preclinical autoimmunity and prevention

TL;DR — RA often develops through a measurable continuum: genetic/environmental susceptibility, systemic autoimmunity, symptoms without clinical synovitis, subclinical imaging inflammation, and classifiable arthritis. ACPA and RF can predate arthritis by years, but most biomarker-positive people do not progress on a fixed timetable; risk is concentrated by antibody level and breadth, symptoms, imaging, genetics, smoking, and time (Greenblatt 2020, PMID 32205569; van Heemst 2014, PMID 24813459). Prevention trials now show that abatacept can delay progression in selected high-risk groups for years after a finite course, while five-year TREAT EARLIER results found no significant overall prevention but a prespecified risk-enriched ACPA-negative subgroup signal (Cope 2026, PMID 41576971; Mulligen 2026, PMID 42392130). Hydroxychloroquine did not prevent RA at 36 months in StopRA (Deane 2026, PMID 40884017). The field has crossed from prediction to intervention, but it has not established a generalizable treatment threshold, acceptable overtreatment, or durable immune tolerance.

A staged continuum, not a single pre-RA state

Stage Observable features What remains uncertain
Susceptibility HLA and non-HLA risk; smoking or mucosal exposures Individual absolute risk
Systemic autoimmunity ACPA, RF, other post-translational antibodies Tissue of origin and time to symptoms
Symptoms without synovitis Inflammatory-pattern arthralgia Specificity of symptom definitions
Subclinical inflammation MRI/ultrasound synovitis, tenosynovitis or osteitis Threshold that justifies treatment
Clinical inflammatory arthritis Examination-confirmed swelling Whether all cases become persistent RA
Classifiable RA 2010 score ≥6/10 or compatible erosive disease Biological heterogeneity within the label

This continuum is useful but not inevitably linear. Biomarkers can fluctuate; symptoms can resolve; some people develop seronegative RA; and imaging abnormalities occur in people who never develop clinical disease (Petrovská 2021, PMID 33746022; Haville 2022, PMID 34991984).

Risk markers

Marker Direction of risk Limitation
High-titer ACPA Higher progression risk Assay/platform and referral spectrum matter
Multiple ACPA specificities Suggests epitope spreading Not standardized for practice
RF plus ACPA Higher risk than either alone Still not deterministic
Inflammatory joint symptoms Enriches risk Symptom definitions vary
MRI inflammation Enriches near-term risk Cost and false positives
Ultrasound power Doppler Objective vascular inflammation Operator and threshold dependence
HLA shared epitope Population susceptibility Low individual predictive value
Smoking Modifiable risk, strongest for ACPA-positive RA Confounding and exposure measurement
Family history Integrates genetic/shared environment Absolute risk remains modest for many

ACPA can be detectable up to ten years before diagnosis, supporting an extended immune phase rather than abrupt joint onset (van Heemst 2014, PMID 24813459). A useful risk model must be calibrated in the intended setting: a first-degree-relative cohort, an ACPA-positive clinic, and a general population have different baseline risks.

Prevention-trial scoreboard

Strategy Population Main finding Interpretation Source
Abatacept, 6 months (ARIAA) ACPA-positive arthralgia plus MRI inflammation Improved MRI inflammation and reduced/delayed RA onset during trial Proof of immune interception; durability unresolved Rech 2024, PMID 38364841; NCT02778906
Abatacept, 12 months (APIPPRA/ALTO) Autoantibody-positive inflammatory joint pain At median 55 months, arthritis-free survival remained 4.9 months longer (95% CI 0.1–9.6; p=0.044), although the difference diminished Demonstrated multi-year delay, not immune tolerance Cope 2026, PMID 41576971
Methotrexate plus glucocorticoid (TREAT EARLIER) Clinically suspect arthralgia plus MRI inflammation Reduced symptoms and MRI inflammation but did not clearly prevent arthritis at primary analysis Disease-burden modification without definitive prevention Krijbolder 2022, PMID 35871815
TREAT EARLIER, 5 years Full cohort and risk-enriched serologic subgroups Overall RA: 22% treatment versus 27% placebo (HR 0.79, 95% CI 0.47–1.34); increased-risk ACPA-negative subgroup: 9% versus 32% (HR 0.24, 0.07–0.87) Overall null result and subgroup benefit must both be retained Mulligen 2026, PMID 42392130
Hydroxychloroquine (StopRA) Anti-CCP3 ≥2× upper limit of normal without arthritis Clinical RA at 36 months: 30.4% HCQ versus 32.9% placebo; risk difference −0.058 (95% CI −0.336 to 0.220; p=0.52) Did not prevent RA Deane 2026, PMID 40884017; NCT02603146

ARIAA was conducted at 14 centers and used MRI inflammation as both enrichment and mechanistic outcome. APIPPRA recruited from 28 UK and three Dutch early-arthritis clinics. ALTO retained 143 of 213 APIPPRA participants and found that the initial delay remained statistically detectable at four years but diminished; disease activity and patient-reported outcomes no longer differed beyond treatment (Cope 2026, PMID 41576971). Different entry criteria and attrition mean these effects should not be pooled casually.

What counts as prevention?

Endpoint Advantage Problem
No arthritis at fixed time Clinically concrete Misses delay beyond time point
Time to arthritis Captures delay Long follow-up required
No classifiable RA Standardized Criteria may shift and require swelling
MRI/ultrasound improvement Mechanistic and sensitive Surrogate not proven to matter to patients
Symptom/function improvement Patient-important Can improve without preventing RA
Drug-free non-progression Strong disease-modification test Hardest endpoint; requires post-treatment follow-up

A six- or twelve-month delay may be valuable, neutral, or harmful depending on drug toxicity, baseline risk, monitoring burden, and patient preferences. Calling all delays “prevention” obscures that tradeoff.

The main harm is treating people who would not otherwise progress. Additional harms include infection, vaccine-response impairment, reproductive constraints, laboratory monitoring, anxiety, medicalization, and opportunity cost. Absolute risk reduction and number needed to treat depend strongly on enrichment criteria; relative effects alone are insufficient.

Shared decisions require explaining three probabilities: untreated progression over a defined horizon, treatment-related reduction or delay, and treatment harm. Presently, these probabilities are not sufficiently transportable across populations for routine preventive prescribing (Frazzei 2023, PMID 36280095; Haville 2022, PMID 34991984).

Prevention outside drugs

As of 2026-08-30, live PubMed searches found no randomized arthritis-onset prevention trial of smoking cessation, periodontal treatment, weight management, diet or microbiome modification in an RA-risk population. The registered REU-stop study evaluates smoking cessation and RA disease activity rather than prevention of first arthritis (NCT02901886); mucosal reviews support plausibility and association, not an established onset-prevention effect (Lucchino 2019, PMID 31295951; Möller 2020, PMID 32582191).

These interventions should not be marketed as proven RA prevention. Their value lies in general health, risk-factor control, and testable hypotheses.

Trial-design priorities

Design choice Minimum requirement
Population Explicit baseline absolute risk and external calibration
Disease definition Examination-confirmed inflammatory arthritis plus prespecified criteria
Treatment period Long enough to test mechanism; followed by drug-free observation
Outcomes Arthritis onset, symptoms, function, imaging, toxicity and treatment burden
Analysis Absolute risks and confidence intervals, not only hazard ratios
Patient involvement Acceptable risk threshold and meaning of “prevention”
Follow-up Capture rebound, delayed onset and sustained drug-free benefit

Prevention estimates and negative controls

Intervention or risk model Quantified result Interpretation
Clinically suspect arthralgia model Clinical features, ACPA and MRI subclinical inflammation independently enriched progression risk (van Steenbergen 2016, PMID 26613769). Risk enrichment is cohort-specific; MRI does not convert arthralgia into RA.
Subclinical synovitis as treatment threshold A substantial fraction of arthralgia patients with imaging synovitis did not progress, creating false-positive overtreatment if imaging alone triggers DMARDs (Rogier 2021, PMID 33331633). Prevention trials need a clinically acceptable positive predictive value, not only association.
PRAIRI rituximab Among 81 ACPA/RF-positive participants, 30 developed arthritis. At 12 months, HR was 0.45 (95% CI 0.154–1.322); treatment delayed the point at which 25% developed arthritis by 12 months (p<0.0001) (Gerlag 2019, PMID 30504445). Delay was clearer than prevention; the confidence interval crossed 1 for the time-specific hazard estimate.
STAPRA atorvastatin Trial stopped at 62 rather than 220 participants; arthritis developed in 29% on atorvastatin versus 19% on placebo (HR 1.40, 95% CI 0.50–3.95) (van Boheemen 2021, PMID 33685928). Inconclusive for efficacy, but decisive evidence that recruitment acceptability can defeat a prevention design.
Dexamethasone Arthritis developed in 20% versus 21% despite temporary ACPA/RF reductions; only one participant per arm met the antibody primary endpoint (Bos 2010, PMID 19363022). Lowering antibody titer transiently is not validated as a surrogate for preventing arthritis.
Abatacept APIPPRA and ARIAA reduced or delayed clinical and imaging progression in selected high-risk groups (Cope 2024, PMID 38364839; Rech 2024, PMID 38364841). Effects during and after treatment, entry criteria, and the acceptability of treating non-progressors differ between trials.

The field’s key controversy is endpoint language. Delaying arthritis, reducing subclinical MRI inflammation, and producing durable drug-free prevention are different claims. New EULAR/ACR risk-stage criteria improve standardization but require external calibration across ancestry, smoking, health-system access, and seronegative trajectories before they can define routine treatment thresholds (van Steenbergen 2025, PMID 40447498). Prevention may be rational at a 50% two-year risk and unacceptable at 10%; absolute risk and number needed to treat must accompany relative effects.

Evidence map

This map adds directly adjacent evidence used to bound interpretation. Inclusion means the record informs this topic or a tightly linked decision; it does not imply that every study supports every conclusion on the page.

Adjacent evidence Relevance to this page
Dedmon LE. The genetics of rheumatoid arthritis. Rheumatology. 2020. (PMID 32638005) Adjacent evidence from classification-and-diagnosis.md, epidemiology-and-burden.md, genetics-environment-and-mucosal-origins.md, overview.md
Kadura S, et al. Rheumatoid arthritis-interstitial lung disease: manifestations, pathogenesis and management. Eur Respir Rev. 2021. (PMID 34168062) Adjacent evidence from classification-and-diagnosis.md, epidemiology-and-burden.md, genetics-environment-and-mucosal-origins.md, overview.md, ra-associated-interstitial-lung-disease.md, red-flags-and-safety-concerns.md
Kim Y, et al. Etiology and pathogenesis of rheumatoid arthritis-interstitial lung disease. 2023. (PMID 37833957) Adjacent evidence from genetics-environment-and-mucosal-origins.md, ra-associated-interstitial-lung-disease.md
Qi XY, et al. Gut microbiota in rheumatoid arthritis: mechanistic insights, biomarkers and translation. 2025. (PMID 40825448) Adjacent evidence from genetics-environment-and-mucosal-origins.md
Frade-Sosa B, et al. Neutrophils, neutrophil extracellular traps, and rheumatoid arthritis. 2023. (PMID 37867028) Adjacent evidence from genetics-environment-and-mucosal-origins.md
Aletaha D, et al. Precision medicine and management of rheumatoid arthritis. J Pers Med. 2020. (PMID 32276742) Adjacent evidence from genetics-environment-and-mucosal-origins.md
Bhamidipati K, et al. Precision medicine in rheumatoid arthritis. Nat Rev Rheumatol. 2022. (PMID 35248489) Adjacent evidence from biomarkers-and-tissue-precision.md, genetics-environment-and-mucosal-origins.md
Humby F, et al. R4RA biopsy-driven rituximab versus tocilizumab. Lancet. 2021. (PMID 33485455) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, clinical-trials-landscape.md, epidemiology-and-burden.md, overview.md, synovial-immunobiology.md
Rivellese F, et al. Synovial biopsy biomarker analysis of R4RA. Nat Med. 2022. (PMID 35589854) Adjacent evidence from biologic-dmards.md, biomarkers-and-tissue-precision.md, clinical-trials-landscape.md, synovial-immunobiology.md, treat-to-target-and-remission.md
Atzeni F, et al. Biomarkers in rheumatoid arthritis. Mediators Inflamm. 2017. (PMID 28825772) Adjacent evidence from biomarkers-and-tissue-precision.md
Perera J, et al. Seropositive and seronegative RA phenotypes, biomarkers and synovium. 2024. (PMID 38727279) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, overview.md
de Pablo P, et al. Imaging tests predicting RA in unclassified arthritis. RMD Open. 2022. (PMID 34782180) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, overview.md
Mandl P, et al. Imaging for treat to target in RA. Rheumatology. 2019. (PMID 31518423) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, epidemiology-and-burden.md, overview.md, treat-to-target-and-remission.md
He S, et al. Plasma protein biomarkers predating onset and treatment response in RA. 2025. (PMID 40691443) Adjacent evidence from biomarkers-and-tissue-precision.md
Ling SF, et al. Pharmacogenetics of methotrexate response in RA. 2020. (PMID 31849277) Adjacent evidence from biomarkers-and-tissue-precision.md, conventional-dmards.md
Caproli A, et al. Calprotectin as a biomarker in RA. 2023. (PMID 37584369) Adjacent evidence from biomarkers-and-tissue-precision.md
Schonfeldova B, et al. Synovial single-cell heterogeneity and zonation. Nat Rev Rheumatol. 2022. (PMID 34559213) Adjacent evidence from biomarkers-and-tissue-precision.md, synovial-immunobiology.md
Grigor C, et al. TICORA tight-control trial. Lancet. 2004. (PMID 15262104) Adjacent evidence from classification-and-diagnosis.md, clinical-trials-landscape.md, epidemiology-and-burden.md, overview.md, treat-to-target-and-remission.md
Korpela M, et al. FIN-RACo five-year outcomes. Arthritis Rheum. 2004. (PMID 15248204) Adjacent evidence from classification-and-diagnosis.md, clinical-trials-landscape.md, conventional-dmards.md, epidemiology-and-burden.md, overview.md, treat-to-target-and-remission.md
Evidence-map records are listed in full below and were live-retrieved from PubMed in this build session.

Open questions

  • Does abatacept alter pathogenesis or chiefly shift time to arthritis? ALTO found a diminishing but still detectable 4.9-month arthritis-free-survival difference at four years (Cope 2026, PMID 41576971).
  • What minimum predicted risk makes preventive immunotherapy acceptable?
  • Can a short combination or mucosal intervention induce drug-free immune tolerance with less overtreatment? (Frazzei 2023, PMID 36280095)
  • Are ACPA-negative and ACPA-positive pre-RA biologically different prevention targets? (Dumoulin 2024, PMID 39303731)
  • Which imaging lesion is a causal intermediate rather than a risk correlate?

References

  1. Greenblatt HK, et al. Preclinical rheumatoid arthritis and rheumatoid arthritis prevention. Curr Opin Rheumatol. 2020;32:289-296. PMID 32205569
  2. van Heemst J, et al. HLA and rheumatoid arthritis: how do they connect?. Ann Med. 2014;46:304-10. PMID 24813459
  3. Cope AP, et al. Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2026;8:e171-e180. PMID 41576971
  4. Mulligen EV, et al. Long-term durability of a time-limited methotrexate intervention in patients with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative arthralgia at increased risk for rheumatoid arthritis (TREAT EARLIER): 5-year data from a double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2026;8:e638-e649. PMID 42392130
  5. Deane KD, et al. A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis. Arthritis Rheumatol. 2026;78:809-820. PMID 40884017
  6. Petrovská N, et al. The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. Autoimmun Rev. 2021;20:102797. PMID 33746022
  7. Haville S, et al. Pre-RA: Can early diagnosis lead to prevention?. Best Pract Res Clin Rheumatol. 2022;36:101737. PMID 34991984
  8. Rech J, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024;403:850-859. PMID 38364841
  9. Krijbolder DI, et al. Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet. 2022;400:283-294. PMID 35871815
  10. Frazzei G, et al. Prevention of rheumatoid arthritis: A systematic literature review of preventive strategies in at-risk individuals. Autoimmun Rev. 2023;22:103217. PMID 36280095
  11. Lucchino B, et al. Mucosa-Environment Interactions in the Pathogenesis of Rheumatoid Arthritis. Cells. 2019;8:700. PMID 31295951
  12. Möller B, et al. Infectious Triggers in Periodontitis and the Gut in Rheumatoid Arthritis (RA): A Complex Story About Association and Causality. Front Immunol. 2020;11:1108. PMID 32582191
  13. van Steenbergen HW, et al. Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis. Ann Rheum Dis. 2016;75:1824-30. PMID 26613769
  14. Rogier C, et al. Subclinical synovitis in arthralgia: how often does it result in clinical arthritis? Reflecting on starting points for disease-modifying anti-rheumatic drug treatment. Rheumatology (Oxford). 2021;60:3872-3878. PMID 33331633
  15. Gerlag DM, et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann Rheum Dis. 2019;78:179-185. PMID 30504445
  16. van Boheemen L, et al. Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial. RMD Open. 2021;7:e001591. PMID 33685928
  17. Bos WH, et al. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann Rheum Dis. 2010;69:571-4. PMID 19363022
  18. Cope AP, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. 2024;403:838-849. PMID 38364839
  19. van Steenbergen HW, et al. EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia. Ann Rheum Dis. 2025;84:1445-1457. PMID 40447498
  20. Dedmon LE, et al. The genetics of rheumatoid arthritis. Rheumatology (Oxford). 2020;59:2661-2670. PMID 32638005
  21. Kadura S, et al. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev. 2021;30:210011. PMID 34168062
  22. Kim Y, et al. Etiology and Pathogenesis of Rheumatoid Arthritis-Interstitial Lung Disease. Int J Mol Sci. 2023;24:14509. PMID 37833957
  23. Qi XY, et al. Gut microbiota in rheumatoid arthritis: Mechanistic insights, clinical biomarkers, and translational perspectives. Autoimmun Rev. 2025;24:103912. PMID 40825448
  24. Frade-Sosa B, et al. Neutrophils, neutrophil extracellular traps, and rheumatoid arthritis: An updated review for clinicians. Reumatol Clin (Engl Ed). 2023;19:515-526. PMID 37867028
  25. Aletaha D, et al. Precision medicine and management of rheumatoid arthritis. J Autoimmun. 2020;110:102405. PMID 32276742
  26. Bhamidipati K, et al. Precision medicine in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2022;36:101742. PMID 35248489
  27. Humby F, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021;397:305-317. PMID 33485455
  28. Rivellese F, et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med. 2022;28:1256-1268. PMID 35589854
  29. Atzeni F, et al. Biomarkers in Rheumatoid Arthritis. Isr Med Assoc J. 2017;19:512-516. PMID 28825772
  30. Perera J, et al. Clinical Phenotypes, Serological Biomarkers, and Synovial Features Defining Seropositive and Seronegative Rheumatoid Arthritis: A Literature Review. Cells. 2024;13:743. PMID 38727279
  31. de Pablo P, et al. Systematic review of imaging tests to predict the development of rheumatoid arthritis in people with unclassified arthritis. Semin Arthritis Rheum. 2022;52:151919. PMID 34782180
  32. Mandl P, et al. The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. Rheumatology (Oxford). 2019;58:2091-2098. PMID 31518423
  33. He S, et al. A longitudinal cohort study uncovers plasma protein biomarkers predating clinical onset and treatment response of rheumatoid arthritis. Nat Commun. 2025;16:6692. PMID 40691443
  34. Ling SF, et al. Pharmacogenetics of methotrexate response in rheumatoid arthritis: an update. Pharmacogenomics. 2020;21:3-6. PMID 31849277
  35. Caproli A, et al. Calprotectin as a biomarker in rheumatoid arthritis: the potential predictive value of response to treatment. Bioanalysis. 2023;15:1111-1113. PMID 37584369
  36. Schonfeldova B, et al. Synovial single-cell heterogeneity, zonation and interactions: a patchwork of effectors in arthritis. Rheumatology (Oxford). 2022;61:913-925. PMID 34559213
  37. Grigor C, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-9. PMID 15262104
  38. Korpela M, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 2004;50:2072-81. PMID 15248204
  39. Dumoulin QA, et al. Development of rheumatoid arthritis after methotrexate in anticitrullinated protein antibody-negative people with clinically suspect arthralgia at risk of rheumatoid arthritis: 4-year data from the TREAT EARLIER trial. Lancet Rheumatol. 2024;6:e827-e836. PMID 39303731